Diabetes treatment has become substantially more complicated to carry out, and the education side of care is adding a component to match.
Healthy Interactions LLC announced on August 5 that its Patient Medication Education Program will be made available as a new benefit through the American Diabetes Association's Education Recognition Program beginning in October 2026. That network includes roughly 1,200 recognized diabetes self-management education and support programs delivering services across 3,554 sites nationwide. The company describes its programs as using facilitated conversation, visual learning, and virtual small-group participation.
Two framing points belong up front. This is a commercial program from a private company, made available through an association recognition pathway rather than developed by the association. And the announcement states plainly that availability through the recognition program does not constitute an American Diabetes Association endorsement of any specific medication, device, or individual treatment decision.
The Clinical Problem Is Genuine
Whatever a reader concludes about the commercial arrangement, the underlying need is not manufactured.
A diabetes regimen twenty years ago frequently meant one or two oral medications and, for some patients, insulin on a fixed schedule. A regimen today can combine several oral agents with different timing and food requirements, one or more injectables including GLP-1 receptor agonists and dual agonists, basal and mealtime insulin with dose adjustment rules, and continuous glucose monitoring feeding data that the patient is expected to interpret and act on.
Each element carries its own instructions. Injectables differ in device design, injection site rotation, storage, and titration schedule. Some oral agents must be taken fasting with specific water volumes and waiting periods. Continuous glucose monitors require sensor changes, calibration in some cases, and an understanding of trend arrows that differs from finger-stick readings.
Barbara Eichorst, the association's vice president for health care programs, noted that starting a new medication or device is an important time for patient education and support, particularly for people managing diabetes and obesity, and described the recognition program as a way to connect people with resources at critical points in care.
Starting a Medication Is the Highest Risk Moment
The timing focus is where this kind of program is most defensible clinically.
Initiation and dose changes are when errors cluster. Hypoglycemia risk rises when insulin or a sulfonylurea is started or increased, particularly if a patient does not know the symptoms or how to treat a low. Gastrointestinal side effects from GLP-1 medications are most pronounced during titration and are a common reason people stop, often without telling anyone.
Device errors are frequent and rarely discussed. Patients inject through clothing, reuse needles, fail to prime pens, inject into scar tissue that impairs absorption, or store insulin at temperatures that degrade it. None of these appear on a prescription label.
Discontinuation is the outcome that matters. A substantial share of patients stop new diabetes medications within the first year, and confusion about how to take them and unmanaged early side effects are documented contributors alongside cost.
Education at initiation addresses a window where a small amount of instruction changes whether a treatment is ever given a fair trial.
What DSMES Is and Why Most Eligible Patients Never Get It
The infrastructure this program plugs into is one many patients have never heard of, which is itself part of the problem.
Diabetes self-management education and support, abbreviated DSMES, is structured education delivered by trained professionals covering how the disease works, nutrition, physical activity, medication use, glucose monitoring, complication prevention, and coping. Programs meeting national standards can be recognized by the American Diabetes Association or accredited through the Association of Diabetes Care and Education Specialists.
Recognition and accreditation matter financially. Medicare Part B covers diabetes self-management training when it is furnished by a recognized or accredited program and ordered by the treating clinician, typically with an initial allotment of hours after diagnosis and follow-up hours annually. Many commercial plans and state Medicaid programs cover it as well.
Despite that, uptake is low. A minority of people with diabetes ever attend a DSMES program, and the reasons include clinicians not referring, patients not knowing it exists, transportation and scheduling barriers, and program closures in rural areas.
The practical takeaway for a reader is a question worth asking: has anyone referred you to diabetes education, and is there a recognized or accredited program near you? The association maintains a public directory of programs.
Reading a Commercial Program Fairly
MedicalDaily's position on vendor announcements is that they deserve neither dismissal nor amplification.
A structured curriculum delivered through an existing accredited network is a reasonable distribution model, and the association's non-endorsement language is appropriate and worth taking at face value. Nothing about this announcement indicates that any particular medication will be promoted.
At the same time, no outcome data accompanies the announcement. There is no evidence presented that this program improves adherence, glycemic control, or hypoglycemia rates compared with standard education. Readers should treat it as a program becoming available, not as a validated intervention.
Patients encountering any medication education material should feel free to ask who produced it and whether any pharmaceutical or device company funded its development. That is a fair question in any clinical setting.
Anyone struggling with a diabetes regimen should raise it directly with their clinician, pharmacist or diabetes care and education specialist rather than adjusting doses independently. Pharmacists in particular are underused for this and can review technique, timing and interactions at no appointment cost in many settings.
Symptoms of severe low blood sugar, including confusion, seizure, or loss of consciousness, are a medical emergency requiring 911. This article is general information and is not medical advice.
Frequently Asked Questions
What was announced? A commercial Patient Medication Education Program will become available through the American Diabetes Association's Education Recognition Program in October 2026.
Is the association endorsing it? No. The announcement states availability does not constitute an endorsement of any medication, device, or individual treatment decision.
How large is that network? Roughly 1,200 recognized programs across 3,554 sites nationwide.
Why is medication education harder now? Regimens increasingly combine multiple oral agents, injectables, and glucose monitoring technology, each with distinct instructions.
When do errors most often occur? At initiation and dose changes, when hypoglycemia risk and side effects are highest.
Is diabetes education covered by insurance? Medicare Part B covers diabetes self-management training through recognized or accredited programs with a clinician's order. Many other plans cover it too.
How do I find a program? Both the American Diabetes Association and the Association of Diabetes Care and Education Specialists maintain public program directories.
